Last reviewed · How we verify
Oral antiplatelet
Oral antiplatelet is a Small molecule drug developed by Capital Medical University. It is currently FDA-approved. Also known as: aspirin 100mg or clopidogrel 75mg.
The oral antiplatelet developed by Capital Medical University is currently marketed, positioning it as an established player in the antiplatelet therapy segment. A key strength of the drug is its patent protection, which extends until 2028, providing a significant barrier to generic competition. The primary risk is the lack of disclosed revenue data, which may limit visibility into its commercial performance and market share.
At a glance
| Generic name | Oral antiplatelet |
|---|---|
| Also known as | aspirin 100mg or clopidogrel 75mg |
| Sponsor | Capital Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
- Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (NA)
- Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention (NA)
- Chaigui Longmu Ejiao Paste for Ischemic Heart Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral antiplatelet CI brief — competitive landscape report
- Oral antiplatelet updates RSS · CI watch RSS
- Capital Medical University portfolio CI
Frequently asked questions about Oral antiplatelet
What is Oral antiplatelet?
Who makes Oral antiplatelet?
Is Oral antiplatelet also known as anything else?
What development phase is Oral antiplatelet in?
Related
- Manufacturer: Capital Medical University — full pipeline
- Also known as: aspirin 100mg or clopidogrel 75mg
- Compare: Oral antiplatelet vs similar drugs
- Pricing: Oral antiplatelet cost, discount & access